Compare Novo Nordisk A/S (NVO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TransMedics Group Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Novo Nordisk A/S is far larger — about 86.8× TransMedics Group Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NVO | TMDX | |
|---|---|---|
Market Cap | $220.53B | $2.54B |
Sector | Health | Technology |
52-Week High | $71.70 | $150.42 |
52-Week Low | $35.29 | $61.99 |
Enterprise Value | $239.49B | $2.94B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
